Karen Worley, PhD, MS

GlaxoSmithKline, US Value, Evidence and Outcomes
Wyoming, OH, United States

Director – Specialty/Immunology

US Value, Evidence and Outcomes (US VEO)

Presentation(s):

• 1494: The Effect of Belimumab on Steroid Use in Patients with SLE: Results from a Retrospective Observational Study of Real-World Data from a US Rheumatology Provider Network

  Monday, November 13, 2023
  9:00 AM – 11:00 AM PT

  Disclosure information not submitted.

• 2351: Health Outcomes Among Patients (Pts) with SLE Initiating Belimumab (BEL) with and Without the Use of Immunosuppressants in the Previous 2 Years

  Tuesday, November 14, 2023
  9:00 AM – 11:00 AM PT

  Disclosure information not submitted.